The British multinational has already acquired the rights to develop and commercialize the respiratory business of the Catalan company
Economy | 2014/11/04 –LA VANGUARDA.com
Barcelona, November 4 (EFE).- Almirall will transfer a total of 719 employees to AstraZeneca UK, the current owner of the Catalan pharmaceutical's respiratory business.
In a note sent to the Comisión Nacional del Mercado de Valores (CNMV), Almirall specified the number of employees of its subsidiaries in Europe, Mexico and Canada, who will be part of the AstraZeneca group.
The company, however, has not said how many workers in each country will be incorporated into the British multinational.
On July 30, Almirall announced it had reached an agreement with AstraZeneca to transfer the rights to the respiratory business for an amount that could reach $2,095 million (€1,562 million).
This proposed transaction ended on Monday, whereby the British multinational already owns the rights to develop and commercialize the respiratory business of the Catalan company, including the rights deriving from previous alliances with third parties and as well as the research of new therapies.
This entitlement also includes drugs such as Eklira (aclidinium), Almirall's lead drug for chronic obstructive pulmonary disease (COPD), which also divested its subsidiary Sofotec Almirall, focused on the development of new inhalers, to AstraZeneca.
The agreement also provides for the transfer of a large part of the employees dedicated to the respiratory tract business to AstraZeneca, including workers from Sofotec, based in Germany.
Almirall, based in Barcelona, is listed on the Spanish Stock Exchange and has a presence in Europe, the United States, Canada and Mexico.
The pharmaceutical controlled by Gallardo brothers it closed the first half of the year with a profit of 19.1 million euros, 8.5% more than in the same period last year.
Follow us on: https://twitter.com/@LaVanguardia | http://facebook.com/LaVanguardia
Related news: AstraZeneca completes acquisition of Almirall's respiratory business.
AstraZeneca strikes deals on cancer drugs
Astrazeneca raises 2014 sales estimates thanks to drug 'Nexium'
